Tommy's Registered charity no 1060508 I FOR ING STREET

# Metabolic profiling of gestational diabetes in obese women during pregnancy

# Sara L White<sup>1</sup>, Dharmintra Pasupathy<sup>1</sup>, Naveed Sattar<sup>2</sup>, Scott M Nelson<sup>3</sup>, Debbie A Lawlor<sup>4,5</sup>, Lucilla Poston<sup>1</sup>, on behalf of UPBEAT Consortium

<sup>1</sup>Division of Women's Health, King's College London, <sup>2</sup> Institute of Cardiovascular and Medical Sciences, University of Glasgow, <sup>3</sup> School of Medicine, University of Glasgow, <sup>4</sup> MRC Integrative Epidemiology Unit at the University of Bristol, <sup>5</sup> School of Social & Community Medicine, University of Bristol, University of Bristol, University of Bristol, University of Bristol, <sup>5</sup> School of Social & Community Medicine, University of Bristol, University of Bristol, University of Bristol, University of Bristol, <sup>5</sup> School of Social & Community Medicine, University of Bristol, University of B

#### Aim

The aim of this study was to describe the biomarker profiles of gestational diabetes (GDM) in an obese cohort at two pregnancy time-points

#### Background

## **Methods**

Pre-existing insulin resistance in obese women is implicated in GDM risk, yet not all obese women develop the disorder.

The prevalence of antenatal obesity is increasing alongside attendant maternal and offspring complications.

The metabolic pathways leading to GDM cand in obese women are not well understood Multi


This prospective cohort study was a secondary analysis using data from the UPBEAT trial (ISRCTN 89971375), a multicentre RCT of intervention in obese pregnant women undertaken in the UK between 2009 and 2014.

646 women (median BMI 35.2kg/m<sup>2</sup>) with complete metabolite data at time-point 1 (mean 17<sup>+0</sup> weeks') and time-point 2 (at oral glucose tolerance test, mean 27<sup>+5</sup> weeks') were included. 198 (30.6%) women developed GDM.

163 metabolites reflecting insulin resistance pathways were measured at both timepoints including 147 from a targeted magnetic resonance (NMR) metabolome and 16 candidate biomarkers (selection shown below).

Multivariate analyses were performed to compare obese GDM women with obese non-GDM women using FDR adjustment for multiple measures.

### Results



#### Interpretation and conclusions

- Multiple significant differences were evident between GDM and non-GDM obese women in diverse pathways. Notable
  differences were found in VLDL subclass lipid constituents, triglyceride content, branched chain and aromatic amino acids,
  glycaemic and fatty acid profiles, adipokines, ketone bodies, liver and inflammatory markers.
- Similar differential patterns are evident both prior to diagnosis and at the time of disease. This supports the earlier identification of women at risk or diagnosis of GDM than currently practised.
- Improved characterisation should contribute to better risk stratification for GDM risk, and targeted intervention or treatment.

#### **References & Funding**

Poston L *et al.* Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology 2015;3:767-777

Funding: Diabetes UK, NIHR, MRC, GSTT & Tommy's Charities; GSTT & KCL BRC, CSO Scotland



Guy's and St Thomas'

King's College Hospital

South London and Maudsley